As of June 30, 2025, DermTech Inc (DMTK) reports a ROE (Return on Equity) of -176.45%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of DermTech Inc's ROE (Return on Equity)
Over recent years, DermTech Inc's ROE (Return on Equity) has shown a stable trend. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2023-12-31 | -176.45% |
| 2022-12-31 | -88.13% |
| 2021-12-31 | -34.11% |
| 2020-12-31 | -57.45% |
| 2019-12-31 | -157.52% |
This slight upward trend highlights how DermTech Inc manages its efficiency in generating profits from shareholders' equity over time.
Comparing DermTech Inc's ROE (Return on Equity) to Peers
To better understand DermTech Inc's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| DermTech Inc (DMTK) | -176.45% |
| Uniqure NV (QURE) | 3547.93% |
| Cytokinetics Inc (CYTK) | 435.49% |
| Abbvie Inc (ABBV) | 128.66% |
| Amgen Inc (AMGN) | 69.59% |
| Regeneron Pharmaceuticals Inc (REGN) | 15.03% |
Compared to its competitors, DermTech Inc's ROE (Return on Equity) is among the lowest compared to peers, which may indicate less effective deployment of shareholders' capital.